-
Colorectal cancer precision medicine! Mercado Keytruda has been approved by the FDA for single-drug first-line treatment of MSI-H/dMMR patients and will change treatment patterns.
Time of Update: 2020-07-18
, June 30, 2020 / bio-valley, -- Merck and Co recently announced that the U.S Food and Drug Administration ( FDA ) has approved the anti-PD-1 therapy Keytruda (Corrida, generic name: pe Mbrolizumab
-
The University of Southern California has teamed up with 10X Genomics to develop new single-cell technology that reveals the genetic diversity of cancer.
Time of Update: 2020-07-18
using a single cell sequencing method based on microdroplets, the researchers sequenced nearly 1500 single cell genomes at the same time, revealing the genetic diversity previously hidden in well studied melanoma cell lines.
-
Chinese research shows that maternal obesity increases the risk of liver cancer in future generations.
Time of Update: 2020-07-18
in this new study, the researchers found a microRNA in the mothers of obese mice, which seemed to be susceptible to liver cancer, thus increasing the possibility of liver cancer development in their offspring and offspring.
-
10 plus tumor genome grouping on the new.
Time of Update: 2020-07-18
multi factor deep learning reveals that Pan cancer genomic tumor clusters have unique immune gene status and response to immunotherapy Abstract in this study, the authors developed a pan cancer deep machine learning model integrating tumor mutation load, microsatellite DNA instability and somatic cell copy number change.
-
Express . . . It is expected to change the standard treatment model, with Merck/Pfizer PD-L1 inhibitors approved for first-line maintenance treatment for urinary skin cancer.
Time of Update: 2020-07-18
Yesterday, Merck KGaA and Pfizer jointly announced that the US FDA has approved the application for SBLA of PD-L1 antibody bavencio (avelumab) for the first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma (UC) patients who have not progressed after platinum containing chemotherapy.
-
Congratulations to Vannosi! The first original new drug was successfully approved for clinical use.
Time of Update: 2020-07-18
effect fnx006 is a new drug developed by Chengdu van Nux Biomedical Technology Co., Ltd., which is used to treat advanced malignant solid tumors such as triple negative breast cancer and melanoma.
-
Q1 Partition Cell Allus High is recommended by cited papers. The team revealed the molecular mechanisms by which lncRNA-SNHG7 promotes the development of lung cancer.
Time of Update: 2020-07-18
in January 2018, Professor He Jianxing from the First Affiliated Hospital of Guangzhou Medical University published the research results entitled "mir-193b availability is inhibited by lncrna ‐ snhg 7 for FAIM 2-induced tumour progress in non ‐ small cell lung cancer" in January 2018, which was firstly found in non-small cell lung cancer (NSCLC), In NSCLC, lncrna-snhg7 plays an important role in the development of NSCLC by competitive binding of mir-193b with Cerna mechanism.
-
How do genetic factors guide CLL treatment decisions in the age of targeted therapy?
Time of Update: 2020-07-18
Tausch and his team evaluated the IGHV mutation status, common genomic abnormalities, and gene mutations in 421 untreated patients in the cll14 trial (nct02242942), and compared the efficacy of altuzumab + nitrogen mustard benzoate (gclb) with Veng, which was recently published in the journal blood.
-
The latest release of the authorities: 2018 global report on esophageal and stomach cancer, China has the highest number of cases.
Time of Update: 2020-07-18
recently, researchers from the international agency for research on cancer (IARC) of the World Health Organization (who) conducted statistics on the number of patients and deaths of esophageal cancer and gastric cancer and their subtypes: esophageal adenocarcinoma and esophageal squamous cell carcinoma; gastric cardia and non cardia gastric cancer in 185 countries around the world in 2018, and compared the proportion and incidence rate of the two cancer subtypes.
-
Express . . . Reducing the risk of disease progression in patients with triple-negative breast cancer was reduced by 59%, and innovative antibody conjugate drugs reached stage 3 clinical endpoint.
Time of Update: 2020-07-18
▎ immunomedics announced today that troldvy (sacituzumab govitecan hziy), an antibody coupled drug developed by the company, has reached the primary end point of progression free survival (PFS) in a confirmatory phase 3 ascent clinical trial for patients with metastatic triple negative breast cancer (mtnbc), reducing the risk of disease progression or death by 59%.
-
Nature Heavyweight: Bypass immune checkpoint IL-18BP restrictions, IL-18 immunotherapy progress again.
Time of Update: 2020-07-18
Image Source: the results of nature mouse colon cancer and melanoma models showed that the tumor inhibitory effect of dr-18 was better than that of IL-18 and PD-1 antibodies.
-
No absolute safe dose! The latest CSCO guidelines teach you how to combat cardiac toxicity with the ring drug.
Time of Update: 2020-07-18
Table 7 In the long-term follow-up of tumor survivors, the mortality of cardiotoxic diseases was the first, anthracycline drugs and radiotherapy were found to be the first cause of childhood tumor The most common factor of cardiotoxicity in tumor patients.
-
Professor Wang Jie: China's first small cell lung cancer guide came out, the authority led the SCLC diagnosis and treatment.
Time of Update: 2020-07-18
initial treatment for patients with extensive stage SCLC without local symptoms and brain metastases: if PS score is 0-2 or 3-4 (due to SCLC), grade I recommends that etoposide + carboplatin + atilizumab is preferred after 4 cycles of sequential atilizumab maintenance therapy (type 1A evidence).
-
Prognosis analysis of methyl transferase-related factors.
Time of Update: 2020-07-18
2. Glioma was classified based on methyl metastasis related genes, and patients were divided into two distinct categories based on the consistency clustering of 50 methyltransferase related genes with the highest change degree in TCGA data (Fig. 1a) C) There are significant differences in prognosis, grade, IDH mutation and other clinical and molecular characteristics between the two groups.
-
Express . . . The FDA approves new treatment options for blood cancer by changing intravenous lystoy.
Time of Update: 2020-07-18
▎ editor of the content team of pharmaceutics, the US Food and Drug Administration (FDA) announced today that it has approved the launch of inqovi (decitabine and cedazuridine) tablets developed by Astex pharmaceuticals of Otsuka pharmaceutical company for the treatment of adult patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).
-
Immunotherapy opens a new journey of bladder cancer diagnosis PD-L1 accurate interpretation is essential.
Time of Update: 2020-07-18
how to establish a unified and standardized PD-L1 detection system and interpretation criteria, to help clinical accurately assess the PD-L1 expression level of patients, so as to screen out potential immunotherapy beneficiaries has become a major topic for pathologists.
-
Yale University: A combination of quercetal monotherapy and chemotherapy can effectively treat invasive endometrial cancer.
Time of Update: 2020-07-18
corresponding author of the study entitled "randomized phase II trial of carboplatin – paclitaxel compared with carboplatin – paclitaxel – trastuzumab in advanced (stage III – IV) or recurrent urethane serous carcinomas that overexpress HER2 / neu (nct01367002): updated overall survival analysis" "This randomized, multi agency, phase 2 trial studied 58 women with uterine serous carcinoma (USC) whose tumors expressed high levels of HER2, which can cause a variety of cancers," Dr. Santin said.
-
This "pulmonary fibrosis and lung cancer" reading cheat, please put it away!
Time of Update: 2020-07-18
Today, let's learn about the series of CT reading films of pulmonary interstitial fibrosis combined with lung cancer ~ let's first look at a group of CT pictures (Fig. 1-3).
Fig. 13 of course, the diagnosis of pulmonary interstitial fibrosis + lung cancer still needs pathological drip.
-
"CD38" and "BCMA" --- the two main battlegrounds for the development of multiple myeloma drugs.
Time of Update: 2020-07-18
mechanism of action of anti-CD38 antibody on MM cells in November 2015, the world's first targeted CD38 antibody darzalex (jointly developed by Johnson & Johnson and genmab) was approved by FDA and used as a single drug in the fourth line treatment of MM patients.
-
What is the accumulation of blood in the abdominal cavity? A benign tumor is also dead!
Time of Update: 2020-07-18
nacif LS's suggestion is similar to the relevant contents of the guidelines in China: if the diameter of the tumor is larger than 6cm, and it is located in the head of pancreas, there is a high risk of malignant transformation, doctors should be more inclined to operate as soon as possible.
